Physician profile
Mohammad M Azam
NPI 1831309087
$1,670.87
in general payments reported to CMS, 2019-2025
15 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.76 · 2021: $105 · 2022: $222 · 2023: $768 · 2024: $333 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011 · Entertainment: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.45 |
| Entertainment | $238.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $414.80 | 2023-2025 | Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $251.78 | 2023 | Aristada, Vivitrol, Lybalvi |
| Curvebeam LLC | $238.21 | 2023 | |
| Abbott Laboratories | $125.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2024 | Invega Sustenna |
| Abbvie INC. | $118.49 | 2019-2022 | |
| Glaxosmithkline, LLC. | $98.05 | 2021-2023 | Shingrix, Arexvy |
| Bioxcel Therapeutics, INC. | $75.87 | 2023 | Igalmi |
| Novo Nordisk INC | $61.83 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $40.86 | 2023 | Uzedy |
| Stryker Corporation | $32.59 | 2025 | Mako |
| Intra-Sana Laboratories | $27.74 | 2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Bayer Healthcare Pharmaceuticals INC. | $24.18 | 2022 | |
| Philips North America LLC | $19.49 | 2022 | |
| Merck Sharp & Dohme LLC | $16.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Azam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.